Unicycive Therapeutics (UNCY) Profit After Tax (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Profit After Tax data on file, last reported at -$12.8 million in Q1 2026.

• Quarterly Profit After Tax fell 2349.82% year-over-year to -$12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$39.9 million (down 145.23% YoY) and the FY2025 annual result came in at -$26.6 million, up 29.79% from the prior year.
• Profit After Tax advanced to -$12.8 million in Q1 2026, from -$14.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $9.9 million in Q2 2024 to a low of -$22.6 million in Q4 2024.
• A 5-year average of -$7.3 million and a median of -$5.6 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax jumped 356.77% — and 2026, when it tumbled 2349.82%.
• Tracing UNCY's Profit After Tax over 5 years: stood at -$5.3 million in 2022, then plunged by 30.09% to -$6.9 million in 2023, then slumped by 226.36% to -$22.6 million in 2024, then soared by 35.15% to -$14.7 million in 2025, then increased by 12.57% to -$12.8 million in 2026.
• The last three Profit After Tax figures came in at -$12.8 million (Q1 2026), -$14.7 million (Q4 2025), and -$6.0 million (Q3 2025), per Business Quant data.